Micafungin nin D developed by Wyeth Pharmaceuticals and

developed by Wyeth Pharmaceuticals and approved by the U

InChiKey: HBOMLICNUCNMMY-XLPZGREQSA-N

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

J Bone Miner Res

Sugiyama K

Micafungin nin D developed by Wyeth Pharmaceuticals andMicafungin, also known as FK463, is a polyene antifungal medication used to treat and prevent invasive fungal infections including candidemia, abscesses and esophageal candidiasis. It inhibits the production of beta 1,3 glucan, an essential component of fungal cell walls. It received final approval from the U. S. Food and Drug Administration (FDA) on March 16, 2005. Micafungin works by way of concentration dependent inhibition of 1,3 beta D glucan